Craft

Consort Medical

Revenue

£305.1 M

FY, 2019

Consort Medical Summary

Company Summary

Overview
Bringing Aesica together with Bespak within the Consort Medical group builds on Bespak’s rich drug delivery device heritage over the last 50 years and Aesica’s decade-long expansion into a leading European pharmaceutical CDMO. Today, Consort Medical is a leading, global, single source drug and delivery device CDMO. Optimising world-class drug delivery device development and manufacture, together with API and finished dose drug formulation and manufacture, within the same group streamlines and accelerates our pharmaceutical customers’ drug route to market. Consort Medical remains at the leading edge of innovation and is committed to investing in patient- and customer-driven innovation with the potential to create new treatments, new markets and new opportunities.
Type
Subsidiary
Status
Active
HQ
Hemel Hempstead, GB | view all locations
Website
http://www.consortmedical.com
Cybersecurity rating
Sectors

Key People

  • Jonathan Glenn, CEO

    • Paul Hayes, CFO

      • Lisa King, Director of Human Resources

        • Keyvan Djamarani, Business President, Bespak

          LocationsView all

          10 locations detected

          • Hemel Hempstead, England HQ

            United Kingdom

            39 Breakspear Way

          • Monheim am Rhein, Nordrhein-Westfalen

            Germany

            Alfred-Nobel- Straße 10

          • Zwickau, Sachsen

            Germany

            Galileistraße 6

          • Pianezza, Piemonte

            Italy

            15 Via Praglia

          • Cambridge

            United Kingdom

            6-7 Technopark Newmarket Road

          • Cramlington, Northumberland

            United Kingdom

            Windmill Industrial Estate Shotton Lane

          and 4 others

          Consort Medical Financials

          Summary Financials

          Revenue (H1, 2020)
          £146.0M
          Gross profit (H1, 2020)
          £146.0M
          Net income (H1, 2020)
          £1.1M
          Cash (H1, 2020)
          £14.8M
          EBIT (H1, 2020)
          £3.2M

          Footer menu